Live
- Naidu pats TDP leaders, cadres for enrolling 73L members
- Rupali Ganguly says for 20 years she never got an award
- Advanced anti-drone systems deployed for devotees’ safety at Mahakumbh
- Workshop on ‘Industry-Academia Practices in Civil Engineering’ concludes
- Revanth assures Kurma community of its due
- 204 cadets pass out of AFA
- Youngest chess king wins laurels for India
- FairPoint: Rahul’s rhetoric falls flat as PM Modi steals spotlight
- Notice issued to SGPC chief Dhami
- PM Surya Ghar scheme set to surpass a decade’s installation growth in a year
Chidambaram slams Centre for 'failing miserably' in rolling out vaccination process for citizens
Senior Congress leader P Chidambaram
Senior Congress leader P Chidambaram on Thursday hit out at Centre for "failing miserably" in rolling out the COVID-19 vaccination for Indians.
New Delhi: Senior Congress leader P Chidambaram on Thursday hit out at Centre for "failing miserably" in rolling out the COVID-19 vaccination for Indians.
"I share the pride that India exported 5.9 crore doses of COVID-19 vaccines. At the same time, I am disappointed that we have administered only 3 crore doses to Indian citizens," Chidambaram tweeted.
"The central government has failed miserably in rolling out the vaccination to Indians. Is there any wonder that the number of infections is rising rapidly every day?" he added.
The former Union Minister also pointed out the need to allow walk-in, on demand vaccination and get rid of the bureaucratic hurdles, including pre-registration.
"Government should allow walk-in vaccination on demand and get rid of bureaucratic hurdles including pre-registration," he further tweeted.
The nationwide COVID-19 vaccination has crossed 3.64 crores coverage, informed the Union Ministry of Health and Family Welfare on Wednesday.
According to the official data, a total of 3,71,43,255 vaccine doses were administered in the country, as per the provisional report till 8 am on Thursday.
The second phase of the vaccination drive started on March 1 in which doses are being administered to people above the age of 60 and those between 45 and 59 years with specific comorbidities.
